Chugai Pharmaceutical develops therapies for bone metabolism and blood disorders, cancer, infectious diseases, immune system disorders, and cardiovascular, kidney, and brain diseases. Products include Neutrogin, which treats white blood cell loss related to chemotherapy; Epogin, which treats red blood cell loss caused by chronic kidney failure; Sigmart, an antianginal agent; and Alfarol for osteoporosis. Chugai Pharmaceuticals has foreign operations in Asia, Europe, and North America through subsidiaries and branch locations. Swiss drugs group
See detailed business credit reports on other businesses or your own.
See detailed profiles for insights and prospects on this company's top competitors.
Essential information for a successful call
EMPLOYEES (This Site)
EMPLOYEES (All Sites)
- ASSETS (MIL USD) 11,830
REVENUE (MIL USD)
- TICKER SYMBOL 4519
- Year Started 1925
- Incorporated 1943
- FISCAL YEAR END DEC
- SALES GROWTH % 14.68%
- NET INCOME GROWTH 36.29%
Get in Touch with 14 Principals*